FDA Approval Summary: Enfortumab Vedotin for Locally Advanced or Metastatic Urothelial CarcinomaElaine Chang, Julia A. Beaver, Kirsten B. Goldberg et al.|Clinical Cancer Research|2020Cited by 186
FDA Approval Summary: Atezolizumab Plus Paclitaxel Protein-bound for the Treatment of Patients with Advanced or Metastatic TNBC Whose Tumors Express PD-L1Preeti Narayan, Julia A. Beaver, Sakar Wahby et al.|Clinical Cancer Research|2020Cited by 185
FDA Approval Summary: Rucaparib for the Treatment of Patients with Deleterious <i>BRCA</i>-Mutated Metastatic Castrate-Resistant Prostate CancerMitchell S. Anscher, Julia A. Beaver, Elaine Chang et al.|The Oncologist|2020Cited by 74
Survival outcomes in older men with non-metastatic castration-resistant prostate cancer treated with androgen receptor inhibitors: a US Food and Drug Administration pooled analysis of patient-level data from three randomised trialsJaleh Fallah, Harpreet Singh, Lijun Zhang et al.|The Lancet Oncology|2021Cited by 15
FDA pooled analysis of time to treatment discontinuation (TTD) in frontline advanced renal cell carcinoma trials.Elaine Chang, Julia A. Beaver, Yutao Gong et al.|Journal of Clinical Oncology|2020Cited by 2